title: Activation of the kallikrein-kinin system by cardiopulmonary bypass in humans.
abstract: We used cardiopulmonary bypass (CPB) as a model of activation of the contact system and investigated the involvement of the plasma and tissue kallikrein-kinin systems (KKS) in this process. Circulating levels of bradykinin and kallidin and their metabolites, plasma and tissue kallikrein, low and high molecular weight kininogen, and kallistatin were measured before, during, and 1, 4, and 10 h after CPB in subjects undergoing cardiac surgery. Bradykinin peptide levels increased 10- to 20-fold during the first 10 min, returned toward basal levels by 70 min of CPB, and remained 1.2- to 2.5-fold elevated after CPB. Kallidin peptide levels showed little change during CPB, but they were elevated 1.7- to 5.2-fold after CPB. There were reductions of 80 and 60% in plasma and tissue kallikrein levels, respectively, during the first minute of CPB. Kininogen and kallistatin levels were unchanged. Angiotensin-converting enzyme inhibition did not amplify the increase in bradykinin levels during CPB. Aprotinin administration prevented activation of the KKS. The changes in circulating kinin and kallikrein levels indicate activation of both the plasma and tissue KKS during activation of the contact system by CPB.
authors.affiliation: St. Vincent's Institute of Medical Research, St. Vincent's Hospital, Fitzroy, Victoria 3065, Australia. J.Campbell@medicine.unimelb.edu.au
authors.forename: D J
authors.initials: DJ
authors.lastname: Campbell
authors.forename: B
authors.initials: B
authors.lastname: Dixon
authors.forename: A
authors.initials: A
authors.lastname: Kladis
authors.forename: M
authors.initials: M
authors.lastname: Kemme
authors.forename: J D
authors.initials: JD
authors.lastname: Santamaria
mesh_terms: D000803:Angiotensin I / Q000097:blood; D000804:Angiotensin II / Q000097:blood; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage; D001158:Arteries; D001798:Blood Proteins / Q000378:metabolism; D001920:Bradykinin / Q000097:blood; D002315:Cardiopulmonary Bypass; D002352:Carrier Proteins / Q000097:blood; D004789:Enzyme Activation / Q000187:drug effects; D006331:Heart Diseases / Q000097:blood* / Q000601:surgery; D006801:Humans; D007609:Kallidin / Q000097:blood; D007704:Kininogens / Q000097:blood; D007705:Kinins / Q000097:blood*; D020842:Plasma Kallikrein / Q000378:metabolism*; D015843:Serpins / Q000097:blood; D020840:Tissue Kallikreins / Q000097:blood*; D014680:Veins
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D001798:Blood Proteins; D002352:Carrier Proteins; D007704:Kininogens; D007705:Kinins; D015843:Serpins; C051324:kallistatin; D000804:Angiotensin II; D007609:Kallidin; D000803:Angiotensin I; D020842:Plasma Kallikrein; D020840:Tissue Kallikreins; D001920:Bradykinin